Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,747 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07590934 | Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer(PROSPECTOR) | recruiting | Phase 1 / Phase 2 | 152 | AstraZenecaINDUSTRY | 7 | Aug 27, 2026 | clinicaltrials |
| NCT03448042 | A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers | active not recruiting | Phase 1 | 123 | Genentech, Inc.INDUSTRY | 13 | Aug 26, 2026 | clinicaltrials |
| NCT04631601 | Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) | terminated | Phase 1 / Phase 2 | 55 | AmgenINDUSTRY | 6 | Aug 26, 2026 | clinicaltrials |
| NCT06016920 | Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 110 | Nykode Therapeutics ASAINDUSTRY | 7 | Aug 26, 2026 | clinicaltrials |
| NCT06892548 | A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer | recruiting | Phase 1 / Phase 2 | 594 | BioNTech SEINDUSTRY | 10 | Aug 26, 2026 | clinicaltrials |
| NCT07691606 | A Study of ARC-02 in B-cell NHL(ABLATE-101) | recruiting | Phase 1 | 140 | Taiho Oncology, Inc.INDUSTRY | 6 | Aug 26, 2026 | clinicaltrials |
| NCT07788677 | Tarlatamab Treatment Before and After Surgery in Surgically Resectable Recurrent High-grade Glioma: a Window of Opportunity Study (TARLAGLIA Study)(TARLAGLIA) | not yet recruiting | Phase 1 | 10 | Vall d'Hebron Institute of OncologyOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT02715284 | Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors(GARNET) | active not recruiting | Phase 1 | 729 | Tesaro, Inc.INDUSTRY | 13 | Aug 25, 2026 | clinicaltrials |
| NCT04165070 | KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) | recruiting | Phase 1 / Phase 2 | 450 | Merck Sharp & Dohme LLCINDUSTRY | 9 | Aug 25, 2026 | clinicaltrials |
| NCT06188702 | S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP | active not recruiting | Phase 1 / Phase 2 | 60 | Servier Bio-Innovation LLCINDUSTRY | 7 | Aug 25, 2026 | clinicaltrials |
| NCT06276491 | Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors | recruiting | Phase 1 | 282 | Xencor, Inc.INDUSTRY | 4 | Aug 25, 2026 | clinicaltrials |
| NCT06533761 | Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML | recruiting | Phase 1 | 125 | Stelexis BioSciencesINDUSTRY | 2 | Aug 25, 2026 | clinicaltrials |
| NCT06586515 | MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors(MOONRAY-01) | recruiting | Phase 1 | 630 | Eli Lilly and CompanyINDUSTRY | 9 | Aug 24, 2026 | clinicaltrials |
| NCT03530397 | A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 | 400 | MedImmune LLCINDUSTRY | 9 | Aug 21, 2026 | clinicaltrials |
| NCT04106219 | A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma | active not recruiting | Phase 1 | 71 | Eli Lilly and CompanyINDUSTRY | 9 | Aug 21, 2026 | clinicaltrials |
| NCT04221542 | Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 479 | AmgenINDUSTRY | 10 | Aug 21, 2026 | clinicaltrials |
| NCT05593094 | A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 210 | Hoffmann-La RocheINDUSTRY | 7 | Aug 21, 2026 | clinicaltrials |
| NCT05765851 | A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 108 | Daiichi SankyoINDUSTRY | 5 | Aug 21, 2026 | clinicaltrials |
| NCT05797168 | Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors(FONTANA) | recruiting | Phase 1 / Phase 2 | 602 | AstraZenecaINDUSTRY | 12 | Aug 21, 2026 | clinicaltrials |
| NCT06179069 | A Study of ZL-1310 in Subjects With Small Cell Lung Cancer | recruiting | Phase 1 | 339 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 3 | Aug 21, 2026 | clinicaltrials |
| NCT07192471 | A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 72 | Kyowa Kirin, Inc.INDUSTRY | 3 | Aug 21, 2026 | clinicaltrials |
| NCT07306559 | A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours) | recruiting | Phase 1 | 187 | Boehringer IngelheimINDUSTRY | 6 | Aug 21, 2026 | clinicaltrials |
| NCT07531095 | Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)(DeLLphi-313) | recruiting | Phase 1 | 160 | AmgenINDUSTRY | 9 | Aug 21, 2026 | clinicaltrials |
| NCT04886804 | Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) | active not recruiting | Phase 1 | 554 | Boehringer IngelheimINDUSTRY | 18 | Aug 20, 2026 | clinicaltrials |
| NCT05101148 | Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas | active not recruiting | Phase 1 | 24 | AstraZenecaINDUSTRY | 4 | Aug 20, 2026 | clinicaltrials |
| NCT05614739 | FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3(FORAGER-1) | recruiting | Phase 1 | 677 | Eli Lilly and CompanyINDUSTRY | 14 | Aug 20, 2026 | clinicaltrials |
| NCT06001788 | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 171 | Kura Oncology, Inc.INDUSTRY | 3 | Aug 20, 2026 | clinicaltrials |
| NCT04104776 | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | recruiting | Phase 1 / Phase 2 | 300 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 19, 2026 | clinicaltrials |
| NCT04725474 | First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)(GDFATHER) | active not recruiting | Phase 1 / Phase 2 | 199 | CatalYm GmbHINDUSTRY | 3 | Aug 19, 2026 | clinicaltrials |
| NCT05142696 | A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab | active not recruiting | Phase 1 / Phase 2 | 55 | Novartis PharmaceuticalsINDUSTRY | 12 | Aug 19, 2026 | clinicaltrials |
| NCT05155332 | A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) | suspended | Phase 1 | 190 | Boehringer IngelheimINDUSTRY | 10 | Aug 19, 2026 | clinicaltrials |
| NCT05356741 | To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers | recruiting | Phase 1 / Phase 2 | 645 | Vir Biotechnology, Inc.INDUSTRY | 5 | Aug 19, 2026 | clinicaltrials |
| NCT06106945 | AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 226 | AstraZenecaINDUSTRY | 9 | Aug 19, 2026 | clinicaltrials |
| NCT06137118 | AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia(SYRUS) | recruiting | Phase 1 / Phase 2 | 255 | AstraZenecaINDUSTRY | 13 | Aug 19, 2026 | clinicaltrials |
| NCT07128303 | Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors | recruiting | Phase 1 | 476 | Gilead SciencesINDUSTRY | 3 | Aug 19, 2026 | clinicaltrials |
| NCT03616587 | Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.(SERENA-1) | active not recruiting | Phase 1 | 396 | AstraZenecaINDUSTRY | 3 | Aug 18, 2026 | clinicaltrials |
| NCT05651932 | A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma | recruiting | Phase 1 | 165 | K36 Therapeutics, Inc.INDUSTRY | 4 | Aug 18, 2026 | clinicaltrials |
| NCT06292780 | A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)(LINKER-AL2) | recruiting | Phase 1 / Phase 2 | 220 | Regeneron PharmaceuticalsINDUSTRY | 6 | Aug 18, 2026 | clinicaltrials |
| NCT06764316 | A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer(BANTAM-01) | recruiting | Phase 1 | 148 | BayerINDUSTRY | 9 | Aug 18, 2026 | clinicaltrials |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,109 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 17, 2026 | clinicaltrials |
| NCT05169515 | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 121 | Hoffmann-La RocheINDUSTRY | 5 | Aug 17, 2026 | clinicaltrials |
| NCT04774718 | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors | active not recruiting | Phase 1 / Phase 2 | 42 | Hoffmann-La RocheINDUSTRY | 11 | Aug 14, 2026 | clinicaltrials |
| NCT05083481 | A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors | terminated | Phase 1 | 226 | Astellas Pharma Global Development, Inc.INDUSTRY | 6 | Aug 14, 2026 | clinicaltrials |
| NCT03332797 | A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer | active not recruiting | Phase 1 | 181 | Genentech, Inc.INDUSTRY | 5 | Aug 13, 2026 | clinicaltrials |
| NCT04170153 | Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) | active not recruiting | Phase 1 | 161 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 5 | Aug 13, 2026 | clinicaltrials |
| NCT05309668 | Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN(SPRINKLE) | active not recruiting | Phase 1 / Phase 2 | 36 | AstraZenecaINDUSTRY | 7 | Aug 13, 2026 | clinicaltrials |
| NCT05407675 | A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 68 | Bristol-Myers SquibbINDUSTRY | 5 | Aug 13, 2026 | clinicaltrials |
| NCT06795022 | First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours(RHEA-1) | recruiting | Phase 1 / Phase 2 | 304 | AstraZenecaINDUSTRY | 7 | Aug 13, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials